Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia-Reference-Cited by-同舟云学术

Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia

Published:2004-01 Issue:1 Volume:45 Page:174-185
ISSN:0022-2275
Container-title:Journal of Lipid Research
language:en
Short-container-title:Journal of Lipid Research

Author:

Bilz Stefan,Wagner Stephan,Schmitz Michaela,Bedynek Andrea,Keller Ulrich,Demant Thomas

Publisher

Elsevier BV

Subject

Cell Biology,Endocrinology,Biochemistry

Reference58 articles.

1. Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy;Grundy;Am. J. Cardiol.,1995

2. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease;Frick;N. Engl. J. Med.,1987

3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S);The Scandinavian Simvastatin Survival Study Group;Lancet.,1994

4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group;Shepherd;N. Engl. J. Med.,1995

5. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators;Sacks;N. Engl. J. Med.,1996

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemia;Frontiers in Endocrinology;2024-02-13

2. Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate;Journal of Lipid Research;2023-03

3. Unravelling lipoprotein metabolism with stable isotopes: tracing the flow;Metabolism;2021-11

4. Triglycerides and cardiovascular disease;Current Opinion in Cardiology;2021-03-31

5. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia;Journal of Clinical Lipidology;2018-09